Asian and Middle East drugmakers interested in doing clinical trials in Russia

The niche of Western pharmaceutical companies that have suspended their clinical trials in Russia may be replaced by their competitors from the Asia Pacific as well as Middle East region, according to recent statements by some leading Russian analysts in the field of pharmaceutical business and some local media, reports The Pharma Letter’s correspondent.

After the exodus of many of Western drugmakers from Russia, a number of pharmaceutical companies from India, South Korea and China have expressed their interest in filling the vacant niches in Russia’s market by conducting clinical trials of their drugs in a view of their further launch in Russia.

Currently the talks are already underway and there is a possibility that the first of such projects will be announced later this year.